The addition of mycophenolate mofetil for suppressing hepatitis B virus replication in liver recipients who developed lamivudine resistance

Transplantation

Volumn 71, Issue 1, 2001, Pages 154-156

  Ben Ari, Ziv ^a   Zemel, Romy ^b   Tur Kaspa, Ran ^a  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; LAMIVUDINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; ALLOGRAFT; ARTICLE; CASE REPORT; DRUG EFFICACY; FEMALE; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOPROPHYLAXIS; LIVER BIOPSY; LIVER TRANSPLANTATION; MALE; PRIORITY JOURNAL; RECIPIENT; RECURRENT INFECTION; VIRUS REPLICATION;

EID: 0035862981     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200101150-00026     Document Type: Article

References (10)

1. Liver transplantation in European patients with the hepatitis B surface antigen
2. Hepatitis B virus reinfection after orthotopic liver transplantation: Serological and clinical implications
3. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis
4. Beneficial effect of lamivudine in recurrent hepatitis B after liver transplantation
5. Long term lamivudine therapy of patients with recurrent hepatitis B post liver transplantation
6. Association of lamivudine resistance in recurrent hepatitis B after liver transplantation with advanced hepatic fibrosis
7. Effect of mycophenolic acid on Epstein-Barr virus infection of human B lymphocytes
8. Polymerase substrate depletion: A novel strategy for inhibiting the replication of the human immunodeficiency virus
9. Mycophenolic acid, an immunosuppressive agent, inhibits HBV replication in cultures of primary and immortalized human hepatocytes
10. Hepatitis B virus precore mutants are identical in carriers from various ethnic origins and are associated with a range of liver disease severity